Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | MMP2 | P08253 | 2/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
| ▸ | COMT | P21964 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | METAP2 | P50579 | 1/20 | 0.55 |
| ▸ | METAP1 | P53582 | 1/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | GMNN | O75496 | 1/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | MMP9 | P14780 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30003476 | 1.00 | TSHR (0.55) | TSHRMMP2CHRM1COMTADRA1A | |
| SCHEMBL1360579 | 0.98 | TSHR (0.53) | TSHRMMP2CHRM1COMTADRA1A | |
| Hydrochloric Acid SCHEMBL27297244 | 0.98 | TSHR (0.53) | TSHRMMP2CHRM1COMTADRA1A | |
| SCHEMBL11497495 | 0.84 | HDAC6 (0.52) | TSHRMMP2CHRM1COMTADRA1A | |
| SCHEMBL30203803 | 0.84 | HDAC6 (0.52) | TSHRMMP2CHRM1COMTADRA1A | |
| SCHEMBL7424652 | 0.79 | KDM4E (0.54) | TSHRMMP2CHRM1COMTADRA1A | |
| SCHEMBL31261655 | 0.79 | KDM4E (0.54) | TSHRMMP2CHRM1COMTADRA1A | |
| SCHEMBL7372603 | 0.79 | PSMD14 (0.55) | TSHRMMP2CHRM1COMTADRA1A | |
| SCHEMBL7344355 | 0.79 | KDM4E (0.54) | TSHRMMP2CHRM1COMTADRA1A | |
| SCHEMBL19303228 | 0.79 | KDM4E (0.54) | TSHRMMP2CHRM1COMTADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117361454-A | Method for preparing hydroxylamine aqueous solution by thermal decomposition of hydroxylamine phosphate | 浙江锦华新材料股份有限公司 | 2024-01-09 | — | — | CN | claimed |
| CN-110465328-B | Process for oximation of ketones | 万华化学集团股份有限公司 | 2022-07-12 | — | — | CN | claimed |
| EP-3666852-B1 | ETCHING SOLUTION HAVING SILICON OXIDE CORROSION INHIBITOR AND METHOD OF USING THE SAME | VERSUM MAT US LLC (US) | 2022-01-05 | — | — | EP | claimed |
| EP-3666852-A2 | ETCHING SOLUTION HAVING SILICON OXIDE CORROSION INHIBITOR AND METHOD OF USING THE SAME | Versum Materials US, LLC (US) | 2020-06-17 | — | — | EP | claimed |
| CN-111197182-A | Etching solution with silicon oxide corrosion inhibitor and method of use thereof | 弗萨姆材料美国有限责任公司 | 2020-05-26 | — | — | CN | claimed |
| US-20200157422-A1 | Etching Solution Having Silicon Oxide Corrosion Inhibitor And Method Of Using The Same | VERSUM MATERIALS US, LLC (US) | 2020-05-21 | — | — | US | claimed |
| US-6620823-B2 | Antiinflammatory agents; rheumatic disorders | BRISTOL-MYERS SQUIBB PHARME COMPANY | 2003-09-16 | — | — | US | claimed |
| CN-1100414-A | Preparation of pharmaceutical compound containing novel derivative of leukol | SMITHKLINE BECKMAN INTERCREDIT (NL) | 1995-03-22 | — | — | CN | claimed |
| EP-0628036-A4 | N-SUBSTITUTED-FURYLALKENYL HYDROXAMIC ACID AND N-HYDROXYUREA COMPOUNDS HAVING LIPOXYGENASE INHIBITORY ACTIVITY. | — | 1995-01-11 | — | — | EP | claimed |
| CN-1027368-C | Process for preparing substituted quinoline derivatives | SMITHKLINE BECKMAN INTERCREDIT (NL) | 1995-01-11 | — | — | CN | claimed |
| EP-0628036-A1 | N-SUBSTITUTED-FURYLALKENYL HYDROXAMIC ACID AND N-HYDROXYUREA COMPOUNDS HAVING LIPOXYGENASE INHIBITORY ACTIVITY | ABBOTT LABORATORIES (US) | 1994-12-14 | — | — | EP | claimed |
| WO-1993017006-A1 | N-SUBSTITUTED-FURYLALKENYL HYDROXAMIC ACID AND N-HYDROXYUREA COMPOUNDS HAVING LIPOXYGENASE INHIBITORY ACTIVITY | ABBOTT LABORATORIES (US) | 1993-09-02 | — | — | WO | claimed |
| US-5169854-A | N-substituted-furylalkenyl hydroxamic acid and N-hydroxyurea compounds having lipoxygenase inhibitory activity | ABBOTT LABORATORIES (US) | 1992-12-08 | — | — | US | claimed |
| CN-1035501-A | PROCESS FOR PREPARING SUBSTITUTED QUINOLINE DERIVATIVES | SMITHKLINE BECKMAN INTERCREDIT (NL) | 1989-09-13 | — | — | CN | claimed |
| JP-60090202-A | — | — | None | — | — | JP | disclosed |
| JP-2157282-A | — | — | None | — | — | JP | disclosed |
| US-12331056-B2 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| JP-S6090202-A | ADSORBING POLYMER AND PRODUCTION THEREOF | ASAHI CHEM IND CO LTD | 1985-05-21 | — | — | JP | disclosed |
| US-3959473-A | DIURETIC | U.S. PHILIPS CORPORATION (US) | 1976-05-25 | — | — | US | disclosed |
| US-3956420-A | CPOLYOLEFIN COMPOSITION FOR ELECTRICAL INSULATIONFERROCENE, 8-SUBSTITUTED QUINOLINE | DAINICHI-NIPPON CABLES, LTD. (JA) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12331056-B2 | SHP2 phosphatase inhibitors and methods of use thereof | PTPRCAP, PTPN22, PTPN1 | TSHR 3144/4885MMP2 2370/4885CHRM1 4862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.